- Home
- CELU
CELU
Celularity Inc.
as 11-15-2024 4:00pm EST
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 40.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $7.97 | Next Earning Date: | 11-07-2024 |
| Revenue: | $42,690,000 | Revenue Growth: | 182.02% |
| Revenue Growth (this year): | -12.08% | Revenue Growth (next year): | 233.89% |
Latest Celularity Inc. News
CELU Breaking Stock News: Dive into CELU Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
GlobeNewswire
25 days ago
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
GlobeNewswire
a month ago
Celularity Provides Corporate Update
GlobeNewswire
a month ago
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal
GlobeNewswire
a month ago
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.
GlobeNewswire
2 months ago
Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
GlobeNewswire
3 months ago
Celularity Appoints Richard J. Berman to its Board of Directors
GlobeNewswire
3 months ago
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Compare CELU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CELU Celularity Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.